Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Development strategy for new cancer drugs going global (CHN、USA、AUS)
-
Computing Power × Human Endeavor × R&D Capability: New Paradigm of Innovative Drug R&D in the AI Era
Stay tuned
AI Medical Technology: From Technical Concepts to Clinical Application
Qingsong Qin, Shanghai Institute for Clinical Innovation & Translation
Computing Power × Human Endeavor: Re-evolution of Innovative Drug R&D Organizations in the AI Era
Jianfeng Peng, Professor of Renmin University of China; Chairman, China Stone
In Silico Workforce in Highly Regulated R&D Scenarios: From Report Generation to Process Quality Control
Hongming Liang, Co-founder & Chief Scientist, Foxu.AI
Hospital GCP × Biotech × CRO × Foxu.AI: Launch of Industrialized Scenarios for Trusted Knowledge Delivery
How Will AI Reshape the Relationship Between Pharma Companies and CRO/CMO in the Next Three Years?
Tong Guo, CEO of Clinical Research Center,GoBroad Healthcare Group
Bingshi Guo, General Manager of Macromolecule R&D Platform, Jeyou Pharma
Hui Zhou, Senior Vice President & Chief R&D Officer for Oncology Pipeline, Innovent Biologics
Lin Xia, Former Senior Reviewer of CDE; Deputy General Manager of TriApex Laboratories & CMO of TriApex (Nanjing)